Loading dose and efficacy of continuous or extended infusion of beta‐lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta‐analysis and meta‐regression analysis
What is known and objective The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performi...
Saved in:
Published in | Journal of clinical pharmacy and therapeutics Vol. 46; no. 2; pp. 424 - 432 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.04.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | What is known and objective
The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performing a systematic review and meta‐analysis.
Methods
PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta‐analysis included 18 randomized controlled trials (RCTs) and 13 non‐RCTs.
Results and discussion
For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72–0.94) and 1.31 (95% CI: 1.15–1.49), respectively. Subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.
What is new and conclusion
CEIs with loading‐dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.
Our subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). According to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA. |
---|---|
AbstractList | What is known and objective
The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performing a systematic review and meta‐analysis.
Methods
PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta‐analysis included 18 randomized controlled trials (RCTs) and 13 non‐RCTs.
Results and discussion
For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72–0.94) and 1.31 (95% CI: 1.15–1.49), respectively. Subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.
What is new and conclusion
CEIs with loading‐dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.
Our subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). According to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA. The role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta-lactams by performing a systematic review and meta-analysis. PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta-analysis included 18 randomized controlled trials (RCTs) and 13 non-RCTs. For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72-0.94) and 1.31 (95% CI: 1.15-1.49), respectively. Subgroup and meta-regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading-dose group (RR: 1.44, 95% CI: 1.22-1.69), which remained significant after adjustments for beta-lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20-1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA. CEIs with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients. The role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta-lactams by performing a systematic review and meta-analysis.WHAT IS KNOWN AND OBJECTIVEThe role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta-lactams by performing a systematic review and meta-analysis.PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta-analysis included 18 randomized controlled trials (RCTs) and 13 non-RCTs.METHODSPubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta-analysis included 18 randomized controlled trials (RCTs) and 13 non-RCTs.For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72-0.94) and 1.31 (95% CI: 1.15-1.49), respectively. Subgroup and meta-regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading-dose group (RR: 1.44, 95% CI: 1.22-1.69), which remained significant after adjustments for beta-lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20-1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.RESULTS AND DISCUSSIONFor CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72-0.94) and 1.31 (95% CI: 1.15-1.49), respectively. Subgroup and meta-regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading-dose group (RR: 1.44, 95% CI: 1.22-1.69), which remained significant after adjustments for beta-lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20-1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.CEIs with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.WHAT IS NEW AND CONCLUSIONCEIs with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients. What is known and objectiveThe role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performing a systematic review and meta‐analysis.MethodsPubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta‐analysis included 18 randomized controlled trials (RCTs) and 13 non‐RCTs.Results and discussionFor CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72–0.94) and 1.31 (95% CI: 1.15–1.49), respectively. Subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.What is new and conclusionCEIs with loading‐dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients. |
Author | Wu, Chih‐Chien Wu, Tung‐Ho Wu, Kuan‐Sheng Yang, Ching‐Shiang Su, Yi‐Chia |
Author_xml | – sequence: 1 givenname: Chih‐Chien orcidid: 0000-0001-5791-4047 surname: Wu fullname: Wu, Chih‐Chien organization: National Yang‐Ming University – sequence: 2 givenname: Yi‐Chia orcidid: 0000-0002-9544-1153 surname: Su fullname: Su, Yi‐Chia email: s19101080@gm.ym.edu.tw organization: National Cheng‐Kung University – sequence: 3 givenname: Kuan‐Sheng surname: Wu fullname: Wu, Kuan‐Sheng organization: Kaohsiung Veterans General Hospital – sequence: 4 givenname: Tung‐Ho surname: Wu fullname: Wu, Tung‐Ho organization: Kaohsiung Veterans General Hospital – sequence: 5 givenname: Ching‐Shiang surname: Yang fullname: Yang, Ching‐Shiang email: csyang429@vghks.gov.tw organization: Kaohsiung Veterans General Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33135261$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAQxy1URLeFCw-ALHFBSCn-SJwst2oFBbQSHMo58sdk8Sqxg-2o3RuPwNtx50nq3exeKoQvY838_jPj8VygM-cdIPSSkiuaz7utHtMV5ZzQJ2hBuagKVlNyhhaEiWVR1qw-Rxcxbgkhomb8GTrnnPKKCbpAf9ZeGus22PgIWDqDoeuslnqHfYe1d8m6yU8R-4DhPoEzYLB13RStd3tEQZJ_f_3upU5yiFkxjDJk5s6mHxlMEAabsi5haQbrbExBpr3WOjzmW47EGdbBply5x7bvHcQI8T2-xnFSm-CnEQ9zIelkv4s2Hno9-gJsQhbss57Cz9HTTvYRXhztJfr-8cPt6lOx_nrzeXW9LjSvalpwBoo2SjdcMsZVQ0tV6-WSAm2YKjuohKpzDEh-djaipAZUpZRQpikN7fglejPnHYP_OUFM7WCjhr6XDvLYWlZWoqkEJyKjrx-hWz-F3G-mKkKbmrMly9SrIzWpAUw7BjvIsGtPX5YBMgM6-BgDdK226TDSPFnbt5S0-61o91vRHrYiS94-kpyy_hOmM3xne9j9h2y_rL7dzpoHZUPRRw |
CitedBy_id | crossref_primary_10_1186_s13613_024_01263_9 crossref_primary_10_1155_2024_9757792 crossref_primary_10_3390_antibiotics12030577 crossref_primary_10_3390_antibiotics12111581 crossref_primary_10_1016_j_iccn_2024_103786 crossref_primary_10_1080_14787210_2023_2184347 crossref_primary_10_1080_17425255_2022_2056012 crossref_primary_10_1016_j_jiac_2023_05_008 crossref_primary_10_3389_fvets_2021_770202 crossref_primary_10_1093_ofid_ofad305 crossref_primary_10_1093_jac_dkad215 crossref_primary_10_1097_CCE_0000000000000823 crossref_primary_10_1556_650_2024_33001 crossref_primary_10_1016_j_jinf_2023_06_023 crossref_primary_10_1007_s40262_023_01230_w |
Cites_doi | 10.1186/cc11405 10.1097/MCC.0b013e3283021b3a 10.5414/CPP43360 10.1177/0885066618784264 10.1007/BF02016564 10.1007/s10096-016-2819-1 10.1164/rccm.201601-0024OC 10.1164/rccm.201505-0857OC 10.1093/jac/dkl478 10.1111/j.1365-2125.2000.00179.x 10.1016/S0924-8579(01)00329-6 10.1128/AAC.01318-06 10.1007/s00134-015-4188-0 10.1086/516284 10.1016/j.ijantimicag.2006.02.020 10.1093/cid/cis856 10.1007/s00134-017-4683-6 10.1086/510590 10.1093/cid/ciu027 10.1186/1471-2288-14-135 10.1016/j.ijantimicag.2014.05.011 10.1093/jac/dkq516 10.1016/j.ijantimicag.2009.10.008 10.1093/cid/ciu402 10.1345/aph.1G467 10.1016/j.ijantimicag.2008.09.012 10.1177/0885066617708756 10.1128/AAC.02759-14 10.1016/j.clinthera.2007.11.003 10.1016/j.clinthera.2012.11.005 10.1177/0962280216669183 10.1345/aph.1S032 10.1093/jac/dkv288 10.4103/0366-6999.205859 10.1002/phar.1875 10.1371/journal.pone.0049845 10.1007/s40262-020-00919-6 10.1002/phar.1310 |
ContentType | Journal Article |
Copyright | 2020 John Wiley & Sons Ltd 2020 John Wiley & Sons Ltd. Copyright © 2021 John Wiley & Sons Ltd |
Copyright_xml | – notice: 2020 John Wiley & Sons Ltd – notice: 2020 John Wiley & Sons Ltd. – notice: Copyright © 2021 John Wiley & Sons Ltd |
DBID | AAYXX CITATION NPM 7T5 7TM 7TO H94 K9. M7N 7X8 |
DOI | 10.1111/jcpt.13301 |
DatabaseName | CrossRef PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Oncogenes and Growth Factors Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1365-2710 |
EndPage | 432 |
ExternalDocumentID | 33135261 10_1111_jcpt_13301 JCPT13301 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Kaohsiung Veterans General Hospital funderid: VGHKS108‐58 – fundername: Kaohsiung Veterans General Hospital grantid: VGHKS108-58 |
GroupedDBID | --- .3N .GA .Y3 04C 05W 0R~ 10A 1CY 1OB 1OC 24P 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAHHS AAJEY AAKAS AANHP AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCMX ACCZN ACFBH ACGFO ACGFS ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOJX ADOZA ADXAS ADZCM ADZMN AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFGKR AFKRA AFPWT AFRAH AFZJQ AHEFC AHMBA AIACR AIAGR AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMSDO BMXJE BROTX BRXPI BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBB EBC EBD EBS EBX ECF ECT ECV EIHBH EJD EMB EMK EMOBN ENC ENX EPT ESX EX3 F00 F5P FEDTE FUBAC FYUFA FZ0 G-S G.N GODZA GWYGA H.X HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PIMPY PQQKQ Q.N Q11 QB0 Q~Q R.K RHX RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 UKHRP V8K W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WUP WVDHM WXI WXSBR XG1 YCJ YFH YOC YUY ZGI ZZTAW ~IA ~WT AAFWJ AAYXX AGQPQ CITATION PHGZM PHGZT NPM 7T5 7TM 7TO H94 K9. M7N 7X8 |
ID | FETCH-LOGICAL-c3571-32eb18bc83a223b814b7c991e182b4fe56b783ae0ded3ae641deb5bb6bd84d1f3 |
IEDL.DBID | DR2 |
ISSN | 0269-4727 1365-2710 |
IngestDate | Tue Aug 05 09:30:28 EDT 2025 Wed Aug 13 09:47:27 EDT 2025 Thu Apr 03 07:05:00 EDT 2025 Thu Apr 24 23:03:56 EDT 2025 Tue Jul 01 03:53:15 EDT 2025 Wed Jan 22 16:29:49 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | pharmacokinetics loading dose antibiotics infectious diseases |
Language | English |
License | 2020 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3571-32eb18bc83a223b814b7c991e182b4fe56b783ae0ded3ae641deb5bb6bd84d1f3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-5791-4047 0000-0002-9544-1153 |
PMID | 33135261 |
PQID | 2501873292 |
PQPubID | 37505 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2456856306 proquest_journals_2501873292 pubmed_primary_33135261 crossref_citationtrail_10_1111_jcpt_13301 crossref_primary_10_1111_jcpt_13301 wiley_primary_10_1111_jcpt_13301_JCPT13301 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2021 2021-04-00 2021-Apr 20210401 |
PublicationDateYYYYMMDD | 2021-04-01 |
PublicationDate_xml | – month: 04 year: 2021 text: April 2021 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | Journal of clinical pharmacy and therapeutics |
PublicationTitleAlternate | J Clin Pharm Ther |
PublicationYear | 2021 |
Publisher | John Wiley & Sons, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc |
References | 1998; 26 2013; 47 2010; 35 1983; 2 2017; 43 1999; 47 2008; 14 2000; 50 2014; 26 2020; 59 2005; 43 2020; 35 2016; 71 2017; 130 2012; 16 2007; 51 2011; 39 2012; 34 2018; 27 2014; 44 2007; 59 2007; 29 2009; 33 2015; 192 2014; 80 2006; 40 2017; 37 2013; 33 2017; 36 2013; 56 2006; 28 2016; 42 2014; 59 2014; 58 2014; 14 2011; 66 2001; 17 2012; 7 2018; 33 2007; 44 2016; 194 Wang Z (e_1_2_6_22_1) 2014; 26 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_30_1 Georges B (e_1_2_6_37_1) 1999; 47 Dhaese S (e_1_2_6_43_1) 2020; 59 Lipš M (e_1_2_6_31_1) 2014; 44 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_34_1 De Waele J (e_1_2_6_38_1) 2014; 80 e_1_2_6_12_1 e_1_2_6_33_1 Georges B (e_1_2_6_17_1) 2005; 43 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_16_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_41_1 Abdul‐Aziz MH (e_1_2_6_8_1) 2016; 71 Rhodes NJ (e_1_2_6_40_1) 2014; 59 Lagast H (e_1_2_6_29_1) 1983; 2 e_1_2_6_9_1 Arnold H (e_1_2_6_11_1) 2011; 39 Gonçalves‐Pereira J (e_1_2_6_28_1) 2012; 7 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 Lorente L (e_1_2_6_19_1) 2007; 29 e_1_2_6_27_1 e_1_2_6_26_1 |
References_xml | – volume: 39 start-page: 10 year: 2011 article-title: Prolonged vs. intermittent infusion of meropenem, piperacillin‐tazobactam, and cefepime for the treatment of life threatening gram‐negative infections in the intensive care unit publication-title: Crit Care Med – volume: 37 start-page: 109 issue: 1 year: 2017 end-page: 119 article-title: Clinical outcomes of extended versus intermittent infusion of piperacillin/tazobactam in critically ill patients: A prospective clinical trial publication-title: Pharmacotherapy – volume: 34 start-page: 2297 issue: 12 year: 2012 end-page: 2300 article-title: Outcomes of extended‐infusion piperacillin‐tazobactam: a retrospective analysis of critically ill patients publication-title: Clin Ther – volume: 194 start-page: 681 issue: 6 year: 2016 end-page: 691 article-title: Continuous versus intermittent beta‐lactam infusion in severe sepsis. A meta‐analysis of individual patient data from randomized trials publication-title: Am J Respir Crit Care Med – volume: 56 start-page: 236 issue: 2 year: 2013 end-page: 244 article-title: Continuous infusion of beta‐lactam antibiotics in severe sepsis: A multicenter double‐blind, randomized controlled trial publication-title: Clin Infect Dis – volume: 58 start-page: 1072 issue: 8 year: 2014 end-page: 1083 article-title: DALI: defining antibiotic levels in intensive care unit patients: are current beta‐lactam antibiotic doses sufficient for critically ill patients? publication-title: Clin Infect Dis – volume: 59 start-page: 905 issue: 6 year: 2014 end-page: 907 article-title: Impact of loading doses on the time to adequate predicted beta‐lactam concentrations in prolonged and continuous infusion dosing schemes publication-title: Clin Infect Dis – volume: 17 start-page: 497 issue: 6 year: 2001 end-page: 504 article-title: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia publication-title: Int J Antimicrob Agents – volume: 29 start-page: 2433 issue: 11 year: 2007 end-page: 2439 article-title: Comparison of clinical cure rates in adults with ventilator‐associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open‐label, historical chart review publication-title: Clin Ther – volume: 80 start-page: 1302 issue: 12 year: 2014 end-page: 1309 article-title: Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis publication-title: Minerva Anestesiol – volume: 71 start-page: 196 issue: 1 year: 2016 end-page: 207 article-title: Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining antibiotic Levels in intensive care unit patients (DALI) cohort publication-title: J Antimicrob Chemother – volume: 59 start-page: 285 issue: 2 year: 2007 end-page: 291 article-title: Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study publication-title: J Antimicrob Chemother – volume: 16 start-page: R113 issue: 3 year: 2012 article-title: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial publication-title: Crit Care – volume: 40 start-page: 219 issue: 2 year: 2006 end-page: 223 article-title: Meropenem by continuous versus intermittent infusion in ventilator‐associated pneumonia due to gram‐negative bacilli publication-title: Ann Pharmacother – volume: 33 start-page: 290 issue: 3 year: 2009 end-page: 291 article-title: Experience with extended‐infusion meropenem in the management of ventilator‐associated pneumonia due to multidrug‐resistant Acinetobacter baumannii publication-title: Int J Antimicrob Agents – volume: 66 start-page: ii25 issue: Supplement 2 year: 2011 end-page: ii31 article-title: Antibiotic dosing in critical illness publication-title: J Antimicrob Chemother – volume: 43 start-page: 304 issue: 3 year: 2017 end-page: 377 article-title: Surviving sepsis campaign: international Guidelines for Management of Sepsis and Septic Shock: 2016 publication-title: Intensive Care Med – volume: 36 start-page: 459 issue: 3 year: 2017 end-page: 466 article-title: Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital‐acquired pneumonia: a randomized controlled trial publication-title: Eur J Clin Microbiol Infect Dis – volume: 14 start-page: 390 issue: 4 year: 2008 end-page: 396 article-title: Better outcomes through continuous infusion of time‐dependent antibiotics to critically ill patients? publication-title: Curr Opin Crit Care – volume: 33 start-page: 1022 issue: 10 year: 2013 end-page: 1034 article-title: Correlation of pharmacokinetic/pharmacodynamic‐derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia publication-title: Pharmacotherapy – volume: 43 start-page: 360 issue: 8 year: 2005 end-page: 369 article-title: Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen publication-title: Int J Clin Pharmacol Ther – volume: 26 start-page: 1 issue: 1 year: 1998 end-page: 10 article-title: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men publication-title: Clin Infect Dis – volume: 7 issue: 11 year: 2012 article-title: Continuous infusion of piperacillin/tazobactam in septic critically ill patients—a multicenter propensity matched analysis publication-title: PLoS One – volume: 35 start-page: 763 issue: 8 year: 2020 end-page: 771 article-title: Evaluation of meropenem extended versus intermittent infusion dosing protocol in critically ill patients publication-title: J Intensive Care Med – volume: 51 start-page: 3304 issue: 9 year: 2007 end-page: 3310 article-title: Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial publication-title: Antimicrob Agents Chemother – volume: 192 start-page: 1298 issue: 11 year: 2015 end-page: 1305 article-title: A multicenter randomized trial of continuous versus intermittent β‐lactam infusion in severe sepsis publication-title: Am J Respir Crit Care Med – volume: 50 start-page: 184 issue: 2 year: 2000 end-page: 191 article-title: Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis publication-title: Br J Clin Pharmacol – volume: 59 start-page: 1237 issue: 10 year: 2020 end-page: 1250 article-title: Prolonged Versus Intermittent Infusion of β‐Lactam Antibiotics: A Systematic Review and Meta‐Regression of Bacterial Killing in Preclinical Infection Models publication-title: Clin Pharmacokinetics – volume: 130 start-page: 1139 issue: 10 year: 2017 end-page: 1145 article-title: Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: A prospective randomized pilot study publication-title: Chin Med J (Engl) – volume: 44 start-page: 357 issue: 3 year: 2007 end-page: 363 article-title: Piperacillin‐tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended‐infusion dosing strategy publication-title: Clin Infect Dis – volume: 44 start-page: 358 issue: 4 year: 2014 end-page: 362 article-title: Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5‐h and 3‐h infusions publication-title: Int J Antimicrob Agents – volume: 27 start-page: 1785 issue: 6 year: 2018 end-page: 1805 article-title: Optimally estimating the sample mean from the sample size, median, mid‐range, and/or mid‐quartile range publication-title: Stat Methods Med Res – volume: 42 start-page: 1535 issue: 10 year: 2016 end-page: 1545 article-title: Beta‐Lactam Infusion in Severe Sepsis (BLISS): a prospective, two‐centre, open‐labelled randomised controlled trial of continuous versus intermittent beta‐lactam infusion in critically ill patients with severe sepsis publication-title: Intensive Care Med – volume: 26 start-page: 644 issue: 9 year: 2014 end-page: 649 article-title: Comparison of 3‐hour and 30‐minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial publication-title: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue – volume: 14 start-page: 135 year: 2014 article-title: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range publication-title: BMC Med Res Methodol – volume: 58 start-page: 4470 issue: 8 year: 2014 end-page: 4475 article-title: Extended‐infusion versus standard‐infusion piperacillin‐tazobactam for sepsis syndromes at a tertiary medical center publication-title: Antimicrob Agents Chemother – volume: 47 start-page: 483 issue: 5 year: 1999 end-page: 485 article-title: Continuous versus intermittent cefepime infusion in critical care. Preliminary results publication-title: Pathol Biol (Paris) – volume: 28 start-page: 122 issue: 2 year: 2006 end-page: 127 article-title: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients publication-title: Int J Antimicrob Agents – volume: 35 start-page: 156 issue: 2 year: 2010 end-page: 163 article-title: First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis publication-title: Int J Antimicrob Agents – volume: 47 start-page: 999 issue: 7–8 year: 2013 end-page: 1006 article-title: Standard versus prolonged doripenem infusion for treatment of gram‐negative infections publication-title: Ann Pharmacother – volume: 2 start-page: 554 issue: 6 year: 1983 end-page: 558 article-title: Treatment of gram‐negative bacillary septicemia with cefoperazone publication-title: Eur J Clin Microbiol – volume: 33 start-page: 134 issue: 2 year: 2018 end-page: 141 article-title: Hospital length of stay among patients receiving intermittent versus prolonged piperacillin/tazobactam infusion in the intensive care units publication-title: J Intensive Care Med – ident: e_1_2_6_13_1 doi: 10.1186/cc11405 – ident: e_1_2_6_4_1 doi: 10.1097/MCC.0b013e3283021b3a – volume: 43 start-page: 360 issue: 8 year: 2005 ident: e_1_2_6_17_1 article-title: Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CPP43360 – ident: e_1_2_6_10_1 doi: 10.1177/0885066618784264 – volume: 2 start-page: 554 issue: 6 year: 1983 ident: e_1_2_6_29_1 article-title: Treatment of gram‐negative bacillary septicemia with cefoperazone publication-title: Eur J Clin Microbiol doi: 10.1007/BF02016564 – volume: 47 start-page: 483 issue: 5 year: 1999 ident: e_1_2_6_37_1 article-title: Continuous versus intermittent cefepime infusion in critical care. Preliminary results publication-title: Pathol Biol (Paris) – ident: e_1_2_6_12_1 doi: 10.1007/s10096-016-2819-1 – ident: e_1_2_6_5_1 doi: 10.1164/rccm.201601-0024OC – ident: e_1_2_6_15_1 doi: 10.1164/rccm.201505-0857OC – ident: e_1_2_6_21_1 doi: 10.1093/jac/dkl478 – ident: e_1_2_6_26_1 doi: 10.1111/j.1365-2125.2000.00179.x – volume: 39 start-page: 10 year: 2011 ident: e_1_2_6_11_1 article-title: Prolonged vs. intermittent infusion of meropenem, piperacillin‐tazobactam, and cefepime for the treatment of life threatening gram‐negative infections in the intensive care unit publication-title: Crit Care Med – ident: e_1_2_6_20_1 doi: 10.1016/S0924-8579(01)00329-6 – volume: 80 start-page: 1302 issue: 12 year: 2014 ident: e_1_2_6_38_1 article-title: Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis publication-title: Minerva Anestesiol – ident: e_1_2_6_35_1 doi: 10.1128/AAC.01318-06 – ident: e_1_2_6_9_1 doi: 10.1007/s00134-015-4188-0 – ident: e_1_2_6_2_1 doi: 10.1086/516284 – volume: 26 start-page: 644 issue: 9 year: 2014 ident: e_1_2_6_22_1 article-title: Comparison of 3‐hour and 30‐minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial publication-title: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue – ident: e_1_2_6_33_1 doi: 10.1016/j.ijantimicag.2006.02.020 – ident: e_1_2_6_16_1 doi: 10.1093/cid/cis856 – ident: e_1_2_6_39_1 doi: 10.1007/s00134-017-4683-6 – ident: e_1_2_6_32_1 doi: 10.1086/510590 – ident: e_1_2_6_3_1 doi: 10.1093/cid/ciu027 – ident: e_1_2_6_7_1 doi: 10.1186/1471-2288-14-135 – volume: 44 start-page: 358 issue: 4 year: 2014 ident: e_1_2_6_31_1 article-title: Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5‐h and 3‐h infusions publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2014.05.011 – ident: e_1_2_6_41_1 doi: 10.1093/jac/dkq516 – ident: e_1_2_6_34_1 doi: 10.1016/j.ijantimicag.2009.10.008 – volume: 59 start-page: 905 issue: 6 year: 2014 ident: e_1_2_6_40_1 article-title: Impact of loading doses on the time to adequate predicted beta‐lactam concentrations in prolonged and continuous infusion dosing schemes publication-title: Clin Infect Dis doi: 10.1093/cid/ciu402 – ident: e_1_2_6_24_1 doi: 10.1345/aph.1G467 – ident: e_1_2_6_25_1 doi: 10.1016/j.ijantimicag.2008.09.012 – ident: e_1_2_6_36_1 doi: 10.1177/0885066617708756 – ident: e_1_2_6_14_1 doi: 10.1128/AAC.02759-14 – volume: 29 start-page: 2433 issue: 11 year: 2007 ident: e_1_2_6_19_1 article-title: Comparison of clinical cure rates in adults with ventilator‐associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open‐label, historical chart review publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.11.003 – ident: e_1_2_6_30_1 doi: 10.1016/j.clinthera.2012.11.005 – ident: e_1_2_6_6_1 doi: 10.1177/0962280216669183 – ident: e_1_2_6_18_1 doi: 10.1345/aph.1S032 – volume: 71 start-page: 196 issue: 1 year: 2016 ident: e_1_2_6_8_1 article-title: Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining antibiotic Levels in intensive care unit patients (DALI) cohort publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkv288 – ident: e_1_2_6_23_1 doi: 10.4103/0366-6999.205859 – ident: e_1_2_6_27_1 doi: 10.1002/phar.1875 – volume: 7 start-page: e49845 issue: 11 year: 2012 ident: e_1_2_6_28_1 article-title: Continuous infusion of piperacillin/tazobactam in septic critically ill patients—a multicenter propensity matched analysis publication-title: PLoS One doi: 10.1371/journal.pone.0049845 – volume: 59 start-page: 1237 issue: 10 year: 2020 ident: e_1_2_6_43_1 article-title: Prolonged Versus Intermittent Infusion of β‐Lactam Antibiotics: A Systematic Review and Meta‐Regression of Bacterial Killing in Preclinical Infection Models publication-title: Clin Pharmacokinetics doi: 10.1007/s40262-020-00919-6 – ident: e_1_2_6_42_1 doi: 10.1002/phar.1310 |
SSID | ssj0006723 |
Score | 2.367286 |
Snippet | What is known and objective
The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains... The role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we... What is known and objectiveThe role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 424 |
SubjectTerms | antibiotics Clinical outcomes Clinical trials Drug therapy infectious diseases loading dose Meta-analysis Mortality Patients pharmacokinetics Sepsis Septic shock |
Title | Loading dose and efficacy of continuous or extended infusion of beta‐lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta‐analysis and meta‐regression analysis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjcpt.13301 https://www.ncbi.nlm.nih.gov/pubmed/33135261 https://www.proquest.com/docview/2501873292 https://www.proquest.com/docview/2456856306 |
Volume | 46 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhp176fmybhiktgZZ48UN-qOQSQkMIbVnKBnIpRpLlELqxw9o-pKf-hP673PNLOiPL3m5bCu1pzWpk2WhGmhl_-oaxV0KHvsqE8QznnAIU4QlfCy-IMwq40DRLykN--JgcnfDj0_h0g-0NZ2F6fogx4UaWYddrMnCpmp-NXF-2U4yw7OEtAmuRR_RpxR2VpLa2G8YYwuO4SztuUgvjGbuu70a_uZjrHqvdcg7vsM_Dw_ZIky_TrlVT_fUXHsf_fZu77LbzRWG_V557bMNU99nOrCezvtqF-epsVrMLOzBb0VxfPWDX72uLv4eibgzIqgBDdBTYE-oSCAJ_XnV110C9hCHVDqjPHeXnSESZVt58-76QupUXDQxoeKDUMBCNBXENYL8W5BrDL7aBo4NtemHt6jXA-WJBS7dp3sI-NJ2yZ1bgoh9IOv4V-6zuv6U564HAFQzND9nJ4bv5wZHnykR4OorTwItC3G8ypbNIoq-jsoCrVKPbazB0Urw0caJSbDM-vib-JDwojIqVSlSR8SIoo0dss6or84RBqRPhZ8oIdCq5lKEsi7RED0v6pZFCmAl7PahLrh2HOpXyWORjLIXzmNt5nLCXo-xlzxzyR6mtQetyt3o0eUgsi2kUinDCXozNaPf0MUdWBucupw_WGZG7JRP2uNfWcZgoCqjsAd78jdW5v4yfHx_M5vbq6b8IP2O3QgL3WAjTFttsl515jt5Zq7atFf4Amko_5Q |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQOcCF92OhwCBQJVCzysN5mFtVUS1lW63QVuotsh0HVWyTapMcyomfwL_jzi9hxvFmWUBIcNpoPY4TecaemXz-hrGXQoe-yoTxDOecAhThCV8LL4gzCrjQNEvKQx4dJ5MTfnganzpsDp2F6fkhhoQbWYZdr8nAKSH9s5Xri3aMIRad3rpKJb1tRPVhzR6VpLa6G0YZwuO4Tzt2UgvkGfpu7ke_OZmbPqvddA5u9pVVG8tVSFiTT-OuVWP9-Rcmx_9-n1vshnNHYa_Xn9vsiqnusJ1Zz2d9uQvz9fGsZhd2YLZmur68y75NawvBh6JuDMiqAEOMFNgT6hIIBX9WdXXXQL2EVbYdUKU7StGRiDKt_P7l60LqVp43sALEA2WHgZgsiG4A-7UgN0h-sQ0cI2zTC2tXsgHOFgtavU3zBvag6ZQ9tgLn_UDSUbDYZ3X_Lc3HHgtcwar5Hjs5eDvfn3iuUoSnozgNvCjELSdTOoskujsqC7hKNXq-BqMnxUsTJyrFNuPja-JPwoPCqFipRBUZL4Iyus-2qroyDxmUOhF-poxAv5JLGcqySEt0sqRfGimEGbFXK33JtaNRp2oei3wIp3AeczuPI_ZikL3oyUP-KLW9UrvcLSBNHhLRYhqFIhyx50Mzmj59z5GVwbnL6Zt1RvxuyYg96NV1GCaKAqp8gDd_bZXuL-Pnh_uzub169C_Cz9i1yfxomk_fHb9_zK6HhPWxiKZtttUuO_MEnbVWPbUm-QNKbkQA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIiEuvB8LBQaBKoGaVR7Ow4hL1bIqpVQrtJV6QZHtOKhim6w2yaGc-An8O-78Emacx7KAkOCUKB7Htjxjz4zH3zD2TGjfVYkwjuGck4EiHOFq4XhhQgYXimZOfsh3x9HBCT88DU832Kv-LkyLDzE43Egy7HpNAr7I8p-FXC_qMVpYdHnrEo_chHh6__0KPCqKbXI3NDKEw3Gb7sBJbRzPUHd9O_pNx1xXWe2eM7nGPvS9bUNNPo2bWo3151-AHP93ONfZ1U4Zhd2We26wDVPcZNvTFs36Ygdmq8tZ1Q5sw3SFc31xi307Km0APmRlZUAWGRjCo8CaUOZAMfBnRVM2FZRL6H3tgAzdkIOOSJSp5fcvX-dS1_K8gj4cHsg3DIRjQWADWK8GuQbxi2XQ4cFWLbHuEjbA2XxOa7epXsIuVI2yl1bgvG1IdgAstq_dt6X52EYCF9AX32Ynk9ezvQOnyxPh6CCMPSfwccNJlE4CicqOSjyuYo16r0HbSfHchJGKscy4OEx8RNzLjAqVilSW8MzLgztssygLc49BriPhJsoI1Cq5lL7MszhHFUu6uZFCmBF73rNLqjsQdcrlMU8HYwrnMbXzOGJPB9pFCx3yR6qtnuvSbvmoUp9gFuPAF_6IPRmKUfDpNEcWBucupRPrhNDdohG723Lr0EwQeJT3AH_-wvLcX9pPD_emM_t2_1-IH7PL0_1JevTm-O0DdsWnQB8bzrTFNutlYx6iplarR1YgfwCJOUK4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Loading+dose+and+efficacy+of+continuous+or+extended+infusion+of+beta%E2%80%90lactams+compared+with+intermittent+administration+in+patients+with+critical+illnesses%3A+A+subgroup+meta%E2%80%90analysis+and+meta%E2%80%90regression+analysis&rft.jtitle=Journal+of+clinical+pharmacy+and+therapeutics&rft.au=Wu%2C+Chih%E2%80%90Chien&rft.au=Su%2C+Yi%E2%80%90Chia&rft.au=Wu%2C+Kuan%E2%80%90Sheng&rft.au=Wu%2C+Tung%E2%80%90Ho&rft.date=2021-04-01&rft.issn=0269-4727&rft.eissn=1365-2710&rft.volume=46&rft.issue=2&rft.spage=424&rft.epage=432&rft_id=info:doi/10.1111%2Fjcpt.13301&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_jcpt_13301 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-4727&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-4727&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-4727&client=summon |